Amgen Inc. (AMGN) will form a joint venture with Chinese pharmaceutical firm Zhejiang Beta Pharma Co. to bring its colon cancer drug Vectibix to the Chinese market.
Zhejiang Beta Pharma will own 51% and Amgen will own the remaining 49% interest in the joint venture, to be named Amgen-Beta Pharmaceuticals Co., the companies said. Read the full story